RLAY Relay Therapeutics, Inc. Forward P/S Multiple

Relay Therapeutics (RLAY) develops targeted oncology therapies through alliances with pharmaceutical behemoths, leveraging its Dynamo platform. Synergy with tech leaders accelerates the discovery of treatments for complex tumors, while AI-driven protein modeling ensures a breakthrough R&D pipeline. The forward P/S valuation history demonstrates a long-term value growth trajectory, while the value of 382.30 captures the metric level at the current stage.

RLAY (relaytx.com) Price to Expected Revenue Ratio history from 07/04/2022 to 11/13/2026

Relay Corp - analytical breakdowns and key metrics (RLAY)

- current price and projected stock value:

Stock Price Relay Therapeutics, Inc.|RLAY - Analyst Target Range

- market capitalization data:

Market Capitalization Relay Corp|RLAY - Total Enterprise Value

- issuer book value statistics:

Accounting Value per Share Relay Therapeutics|RLAY - Total Net Assets|Market Capitalization to Book Value Ratio relaytx.com|RLAY - Company Assets

- debt and liquidity data:

- net income and valuation multiples indicators:

RLAY - Company Net Income|Expected Profit Relay Therapeutics|RLAY - Company Value to Net Income|Forward P/E Multiple Relay Pharma|RLAY - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Relay Corp|RLAY - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share for the last 12 months Relay Therapeutics|RLAY - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months relaytx.com|RLAY - Earnings per share increase in current year|Earnings growth forecast for next year Relay Therapeutics

- issuer revenue and sales details:

RLAY - Company Total Revenue|Company Projected Revenue Relay Therapeutics, Inc.|RLAY - Price-to-Revenue Ratio|Forward P/S Multiple Relay Corp

Summary company analysis:Relay Therapeutics, Inc. (RLAY)

Relay Therapeutics' innovative approach to developing oncology drugs through structural biology is reflected in its projected market cap-to-revenue ratio. Unlike retrospective reports, this indicator compares the company's market value with expected future earnings. The metric is calculated by dividing the current market capitalization by projected sales volume to measure the degree of valuation premium. Low values minimize the risk of overpayment, yet they signal a potential stagnation in the development of the business model.

Competing companies